MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study

• DOI: 10.1111/jgh.16261
• Publication Date: 2023-06-16T00:35:56Z
• Authors: Eugene Han; Ho Soo Chun; Yong‐ho Lee; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Byung‐Wan Lee; Eun Seok Kang; Bong‐Soo Cha; Sang Hoon Ahn; Seung Up Kim
• Keywords: Metabolic dysfunction-associated fatty liver disease; Sarcopenia; Non-alcoholic Fatty Liver Disease; Cardiovascular Diseases; Risk Factors; Heart Disease Risk Factors; Liver fibrosis; 610; Humans; Cardiovascular disease; 3. Good health; Non-alcoholic fatty liver disease

Clinical features of non-alcoholic fatty liver disease (NAFLD), but not fulfilling the diagnostic criteria metabolic dysfunction-associated (MAFLD), remain unclear. We investigated risk sarcopenia and cardiovascular (CVD) in MAFLD non-metabolic (MR) NAFLD. Subjects were selected from Korean National Health Nutrition Examination Surveys 2008-2011. Liver steatosis was assessed using index. Significant fibrosis defined fibrosis-4 index, categorized by age cut-offs. Sarcopenia as lowest quintile Atherosclerotic CVD (ASCVD) score > 10% high probability. A total 7248 subjects had (137 with non-MR NAFLD, 1752 MAFLD/non-NAFLD, 5359 overlapping NAFLD). In NAFLD group 28 (20.4%) significant fibrosis. The (adjusted odds ratio [aOR] = 2.71, 95% confidence index [CI] 1.27-5.78) probability ASCVD (aOR 2.79, CI 1.23-6.35) significantly higher MAFLD/non-NAFLD than (all P < 0.05). similar between without However, 3.38 for 3.73 ASCVD; all risks did differ according to fibrotic burden group. might be better identifying high-risk criteria.